C

Cooper University HealthCare | MD Anderson Cancer Center at Cooper

Research site
(Unclaimed)
Location
Two Cooper Plaza, 400 Haddon Avenue, Camden, New Jersey, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 26
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Enrolling
Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo
Locations recently updated

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination wit...

Enrolling
Relapsed or Refractory Follicular Lymphoma
Drug: Lenalidomide
Drug: Rituximab

This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance tr...

Active, not recruiting
FIGO Stage III-IV
Newly Diagnosed
Drug: Rucaparib
Drug: Placebo Oral Tablet

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus...

Enrolling
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Drug: 5-Fluorouracil
Drug: Capecitabine

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of...

Enrolling
Multiple Myeloma
Drug: Pomalidomide
Drug: Elotuzumab

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling
Breast Neoplasms
Drug: Letrozole
Drug: Tamoxifen

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase...

Enrolling
Solid Tumor
Drug: Farletuzumab ecteribulin
Drug: Prednisolone
Locations recently updated

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetax...

Enrolling
Prostate Cancer
Drug: Radium-223
Drug: Docetaxel 60 mg/m2

IMGN853-0420 is a multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continua...

Enrolling
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patient...

Active, not recruiting
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Other: Best Standard of Care
Device: NovoTTF-200M device

This is a randomized, blinded, non-comparative, two-arm Phase 2 clinical trial to assess the efficacy and safety of AGEN2034 administered with placeb...

Active, not recruiting
Cervical Cancer
Drug: AGEN2034
Drug: AGEN1884

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combinatio...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum r...

Active, not recruiting
Platinum-resistant Ovarian Cancer
Drug: Afuresertib
Drug: Paclitaxel

Trial conditions

Ovarian Epithelial Carci... (4 trials)
Ovarian Cancer (4 trials)
Breast Cancer (3 trials)
Adenocarcinoma (2 trials)
Brain Cancer (2 trials)
Fallopian Tube Cancer (2 trials)
Lung Cancer (2 trials)
Lymphoma (2 trials)
Neoplasm Metastasis (2 trials)
Pancreatic Cancer (2 trials)

And 20 more

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems